- Previous Close
0.3500 - Open
0.3350 - Bid --
- Ask --
- Day's Range
0.3350 - 0.3970 - 52 Week Range
0.3000 - 2.0000 - Volume
150,612 - Avg. Volume
15,835 - Market Cap (intraday)
1.801M - Beta (5Y Monthly) 0.16
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5900 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Medesis Pharma S.A. operates as a biopharmaceutical company. The company's products include NanoLithium (NP03) for the treatment of Alzheimer's disease; NanosiRNA HD and NanoP42T to treat Huntington's disease; NanoLithium for the prevention and treatment of psychiatric disorders; NanoManganese (NP02), a radiation protection drug; and NU01 plutonium decorporation and NU02 cesium decorporation nuclear drugs. It also develops oncology drugs, including NanosiRNA IFNAR and NanoManganese Radiotherapy Glioblastoma. The company was founded in 2003 and is based in Montpellier, France.
www.medesispharma.comRecent News: ALMDP.PA
View MorePerformance Overview: ALMDP.PA
Trailing total returns as of 4/10/2025, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALMDP.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALMDP.PA
View MoreValuation Measures
Market Cap
1.80M
Enterprise Value
2.86M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
28.30
Price/Book (mrq)
--
Enterprise Value/Revenue
44.89
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-115.30%
Return on Equity (ttm)
--
Revenue (ttm)
63.64k
Net Income Avi to Common (ttm)
-3.13M
Diluted EPS (ttm)
-0.5900
Balance Sheet and Cash Flow
Total Cash (mrq)
24.75k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--